SCHEDULE 13G: Farallon Capital Entities Disclose 6.6% Passive Stake in Tango Therapeutics

Farallon Capital and its affiliated entities have filed a Schedule 13G, revealing a collective beneficial ownership of 7,182,000 shares, representing 6.6% of Tango Therapeutics, Inc.'s common stock.

Summary

• Farallon Capital Partners, L.P., along with several affiliated funds and their general partners, collectively reported beneficial ownership in Tango Therapeutics, Inc.
• The aggregate beneficial ownership attributed to the Farallon Individual Reporting Persons, who are managing members or senior managing members of the Farallon General Partner, is 7,182,000 shares.
• This collective stake represents 6.6% of the common stock of Tango Therapeutics, Inc.
• The filing indicates that the shares are held for investment purposes and not with the intent to change or influence control of the issuer.
• Individual Farallon funds hold varying percentages of the class, including Farallon Capital Partners, L.P. with 1.1% (1,145,398 shares), Farallon Capital Institutional Partners, L.P. with 1.5% (1,627,113 shares), and Farallon Capital Offshore Investors II, L.P. with 2.8% (2,984,329 shares).

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership, carrying a neutral sentiment. It indicates a significant investment but provides no operational or financial performance details.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of a significant passive investment by a hedge fund or investment manager in a publicly traded company, common in the biotechnology or pharmaceutical sector where Tango Therapeutics operates. It indicates a notable institutional investor's confidence in the company's long-term prospects without seeking active management influence.

Stakeholder Impact

• Shareholders: The disclosure of a significant passive stake by a reputable investment firm like Farallon Capital may be viewed positively, potentially signaling institutional confidence in Tango Therapeutics, Inc. and its future prospects.

Key Dates

Keywords

Tango Therapeutics, Farallon Capital, Schedule 13G, Beneficial Ownership, Common Stock, Investment, SEC Filing, Passive Investor